Caisse Des Depots ET Consignations Takes $637,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Caisse Des Depots ET Consignations bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,540 shares of the company's stock, valued at approximately $637,000.

Other large investors have also modified their holdings of the company. Cerity Partners LLC boosted its position in IDEXX Laboratories by 25.2% during the third quarter. Cerity Partners LLC now owns 10,924 shares of the company's stock worth $5,519,000 after acquiring an additional 2,202 shares during the last quarter. Kingsview Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $507,000. Centaurus Financial Inc. purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $115,000. Brown Brothers Harriman & Co. grew its position in shares of IDEXX Laboratories by 4.4% in the third quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company's stock valued at $375,000 after purchasing an additional 31 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of IDEXX Laboratories by 3.6% in the third quarter. FMR LLC now owns 290,861 shares of the company's stock valued at $146,949,000 after purchasing an additional 10,017 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 1.5 %

IDEXX Laboratories stock traded up $6.33 during trading on Tuesday, hitting $426.28. The company had a trading volume of 185,960 shares, compared to its average volume of 581,784. The stock has a market cap of $34.55 billion, a price-to-earnings ratio of 40.00, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88. The company's 50 day simple moving average is $437.08 and its 200-day simple moving average is $442.03.

Remove Ads

Analyst Ratings Changes

Several analysts have issued reports on the company. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday, March 25th. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price on the stock. Finally, Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.